Fidelity's reduction below 5% removes any filing obligation to report further decreases, so the next public update may only come with the next 13F filing. Monitor for any conversion to a 13D if Fidelity's intentions change, but the passive certification makes that unlikely.
RPRX drugs
RPRX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $67.57entry
- T+1 · 11d ago −0.40%α −0.71% · $67.30
- T+5 · 5d ago +2.07%α −1.22% · $68.97
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
FMR LLC (Fidelity) filed an amended Schedule 13G disclosing a 4.3% passive stake in Royalty Pharma plc as of September 30, 2026, down from prior filings. The filing is routine and reflects a reduction in Fidelity's holdings, but the stake remains below the 5% threshold, indicating continued passive ownership without activist intent.
Key Financial Metrics
Key Facts
- FMR LLC reported beneficial ownership of 19,288,880.43 shares of Royalty Pharma Class A common stock as of September 30, 2026.
- The stake represents 4.3% of shares outstanding, down from prior filings where the stake was above 5%.
- Fidelity filed as a passive investor under Rule 13d-1(b), certifying shares were not acquired to influence control.
- The filing is an amendment to a Schedule 13G, not a 13D, confirming no activist intent.
- Abigail P. Johnson, Chairman and CEO of FMR LLC, is also reported as a beneficial owner of the same 4.3% stake.
Financial Impact
FMR LLC holds 19,288,880 shares valued at approximately $1.1B based on market cap of $38.2B and 4.3% stake.
Risk Factors
- Fidelity's stake reduction could signal reduced institutional confidence, though the filing is routine for a passive manager.
- No specific risk identified from this filing alone.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0000315066-26-002829 |
| Document: 0000315066-26-002829-index-headers.html | 0000315066-26-002829 |
| Document: 0000315066-26-002829-index.html | 0000315066-26-002829 |
| Document: 0000315066-26-002829.txt | 0000315066-26-002829 |
Track record
23 reports on RPRX
5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +15.20% at T+60 after the May 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $69.02 Now $68.53 −0.72% settles Nov 24
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Viewing Entry $67.57 to $68.97 Now $68.53 +1.41% ▲ +2.07% −1.22% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $67.56 to $70.01 Now $68.53 +1.43% ▲ +3.63% +4.54% vs SPY
- Sep 30, 20266w ago Insider Cluster Bearish 5/10 Entry $57.63 to $56.21 Now $68.53 −18.91% ▲ +2.46% +3.77% vs SPY
- Sep 4, 202610w ago Press Release Bearish 5/10 Entry $60.59 to $58.47 Now $68.53 −13.10% ▲ +3.50% +2.38% vs SPY
- Aug 19, 202612w ago Insider Cluster Neutral 3/10 Entry $60.57 to $61.92 Now $68.53 +13.14% ▲ +2.24% +1.12% vs SPY
- Aug 12, 202613w ago 144 Neutral 3/10 Entry $58.56 to $60.58 Now $68.53 +17.02% ▲ +3.45% +5.41% vs SPY
- Aug 5, 202614w ago 8-K Bullish 6/10 Entry $57.75 to $59.22 Now $68.53 +18.66% ▲ +2.55% +2.19% vs SPY
- Jul 2, 202619w ago Insider Cluster Neutral 2/10 Entry $57.77 to $57.96 Now $68.53 +18.62% ▲ +0.33% −0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers